TL;DR: The cannabis sector enters Thursday’s July 9 session with Q2 2026 earnings season approaching its decisive reporting window, as Green Thumb Industries, Curaleaf Holdings, and Canopy Growth all report in early August. Sector internals were mixed Wednesday with Canadian LPs diverging from U.S. MSO action on regulatory headlines and currency dynamics. Key institutional watch levels remain intact ahead of a busy next four weeks.
Market Analysis
Cannabis equities closed Wednesday July 8 with mixed internals as U.S. multi-state operators broadly held trend lines established since the post-holiday advance. With Q2 2026 reporting windows rapidly approaching — Green Thumb Industries (OTCQX: GTBIF) on August 4, Curaleaf Holdings (OTCPK: CURLF) on August 5, and Canopy Growth (NASDAQ: CGC) on August 7 — institutional positioning entering Thursday reflects the sector’s transition from macro catalysts to fundamental delivery.
CURLF, the sector’s largest U.S. operator by revenue, continues to trade in a range supported by a remarkable 1-year return of over 320% against a backdrop of operational streamlining and portfolio rationalization. Average daily volume near 455,000 shares reflects sustained institutional interest ahead of the August 5 earnings call, where management is expected to provide early Q2 color on retail performance and state-level EBITDA margins. Q1 FY2026 revenue came in at $324.23 million, anchoring the thesis that Curaleaf’s national retail footprint — the largest in the U.S. industry — is generating the revenue density required to justify its current enterprise value.
GTBIF held near $7.60 entering Thursday morning, supported by its status as one of the only U.S. cannabis operators with a consistent positive earnings record — trailing P/E of 14.90 on diluted EPS of $0.51. Q1 FY2026 revenue reached $300.19 million, and analysts carrying a $15.67 average price target see meaningful multiple expansion if Q2 execution continues to demonstrate the profitability floor that distinguishes Green Thumb from its peer group. At a market cap of approximately $1.664 billion and an enterprise value-to-EBITDA of 3.85x, GTBIF remains one of the most institutionally credible valuations in the cannabis sector.
Canadian LPs present a different risk profile heading into the August reporting cycle. Tilray Brands (NASDAQ: TLRY) fell 2.60% Wednesday to $4.49, continuing to navigate the structural transition from cannabis-only to diversified beverage and pharmaceutical platform. The 52-week range of $4.10 to $23.20 reflects the extreme sentiment swings that have characterized TLRY’s investor base. Canopy Growth (NASDAQ: CGC) edged up 1.59% to $0.9651 — near the $1.00 psychological threshold that institutional desk screens frequently reference as a minimum price qualifier.
Regulatory and Market Context
The regulatory backdrop entering Thursday’s session continues to be defined by the DEA’s ongoing Cannabis Schedule III rescheduling proceeding. Each week without reversal of the Department of Justice’s 2024 recommendation strengthens the base market expectation that rescheduling is completed before the end of 2026. The most tangible near-term impact for U.S. MSOs would be relief from IRC Section 280E — the federal tax provision that currently denies standard business deductions to cannabis operators, producing effective federal tax rates far above pre-tax margins for companies like CURLF, GTBIF, and Verano Holdings.
State-level legislative momentum continues to underpin the sector’s fundamental revenue outlook. Several states remain in active adult-use licensing expansion phases, with the regulatory pipeline for Q3 and Q4 2026 expected to introduce new retail market access in population-dense markets. For multi-state operators with existing conditional licenses and established brand infrastructure, each incremental state activation represents a capital-efficient revenue lever within the existing operating cost base.
The broader macro context is also constructive entering Thursday. Equity markets have been broadly supportive of higher-beta sectors through the first week of July, and cannabis names — despite their OTC and micro-cap classification — have shown correlation with risk-on sentiment that institutional allocators have begun to monitor more closely as rescheduling approaches.
Conclusion
Thursday’s July 9 session sets up as a consolidation phase ahead of what is expected to be the most consequential reporting window the U.S. cannabis sector has seen since the 2024 rescheduling recommendation. With GTBIF reporting August 4, CURLF August 5, and CGC August 7, the next 26 days represent the sector’s fundamental inflection point for the second half of 2026. Execution on Q2 revenue and margin guidance will determine whether the sector’s year-to-date gains extend into a broadening institutional narrative or retrace into a more selective quality-only bid.
Investors tracking real-time price movements and sector developments should monitor the cannabis stock tracker for updated quotes, volume analysis, and sector rotation signals as earnings season approaches.